Alere Receives $12.9 Million Funding for Next Gen POC Flu Test
Alere Inc. has entered into a contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to develop diagnostic countermeasures for pandemic influenza.
Under the terms of the 3.5 year contract, BARDA will provide up to $12.9 million to support the development of a rapid, molecular, low-cost influenza diagnostic device with PCR-like performance at the point-of-care. The project is designed to help support future preparedness and medical response to an influenza pandemic. Funding from BARDA is subject to successful completion of various interim feasibility and development milestones as defined in the agreement. In connection with Alere’s development of a rapid, molecular, low-cost influenza diagnostic device, Alere will be responsible for conducting clinical trials to support FDA 510(K) clearance and obtaining CLIA waiver as well as manufacturing and commercializing the resulting molecular influenza test.
Alere will use the funding to develop the next generation of its current Alere™ i Influenza A & B test, which improves rapid flu testing by providing highly accurate, molecular results in under 15 minutes. Alere i Influenza A & B was launched in January 2014 in Europe and received clearance from the U.S. Food and Drug Administration (FDA) in June 2014.
The next-generation product platform will be intended for even more widespread use outside of the traditional healthcare system, while not compromising the level of clinical performance.
Advanced development of Alere’s next-generation molecular influenza test is part of BARDA’s comprehensive approach to developing medical countermeasures for pandemic flupreparedness. The program includes developing vaccines, therapeutics, diagnostics and non-pharmaceutical countermeasures for influenza preparedness and building and sustaining facilities for their domestic manufacturing.
Date Published: October 6, 2014
Source article link: Alere, Inc » company contact details
Are You Prepared for the Flu Season Ahead?
Discover VirClia®, Chemiluminescence in Monotest That Adapts to Your Lab
Flu Season Still to Reach Peak
Sekisui OSOM® Ultra Flu A&B Test Using Swab Samples
CE Marked 30 Minute Or Less Molecular Flu/RSV Test